Sumitomo Dainippon Pharma Co Ltd's Fiscal Year is From April To March - All Figures are in JPY, Billions.
The item "Total-Other-Finance-Cost" stands at -47.40 Billion Japanese Yens for the trailing twelve months (TTM) period ending 09/30/2025.
Sumitomo Dainippon Pharma Co Ltd's second quarter result of -16.27 Billion JPY for the item "Total Other Finance Cost" represents a decrease of -79.76 percent compared to it's first quarter result.
Also, Sumitomo Dainippon Pharma Co Ltd's second quarter result of -16.27 Billion JPY for the item "Total Other Finance Cost" represents an increase of 30.48 percent compared to it's second quarter result of last year.
Looking again at the trailing twelve months series (TTM), Sumitomo Dainippon Pharma Co Ltd's second quarter result of -47.40 Billion JPY for the item "Total Other Finance Cost" represents an increase of 13.08 percent compared to it's first quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an decrease of -21.97 Billion Japanese Yens compared to the value the year prior.
The 1 year change is -21.97 Billion Japanese Yens.
The 3 year change is -46.64 Billion Japanese Yens.
The 5 year change is -42.74 Billion Japanese Yens.
The 10 year change is -46.46 Billion Japanese Yens.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Total Other Finance Cost | 905,699,262,464.00 |
![]() | Johnson & Johnson - Total Other Finance Cost | 486,508,953,600.00 |
![]() | AbbVie Inc - Total Other Finance Cost | 399,570,305,024.00 |
![]() | Roche Holding AG - Total Other Finance Cost | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Total Other Finance Cost | 280,205,508,085.11 |